For detection of MRD in AML samples using flow cytometry a comprehensive panel of markers is used including early/stem cell markers(CD34 and CD 117) in addition to myeloid lineage and differentiation markers(CD2, CD7, CD19, CD56) to track aberrant AML blasts. This evidence concerns the gene NCAM1 and acute myeloid leukemia.